tbuckley/cabot-search huggingface dataset:
Progress Toward Poliomyelitis Eradication—Eastern Mediterranean Region, 1999-September 2000
Journal: JAMA (2001)

In 1988, the Regional Committee for the Eastern Mediterranean Region (EMR) of the World Health Organization (WHO) adopted a resolution to eradicate poliomyelitis from the region by 2000. Since then, substantial progress has been made in vaccination and surveillance and, by the end of the year, 19 of the 23 EMR countries are expected to have interrupted poliovirus transmission. This report summarizes progress toward this goal from January 1999 through September 2009.
My Ambition
Authors: Phillip J. Cozzi
Journal: Annals of Internal Medicine (1998)

Ad Libitum1 May 1998My AmbitionPhillip J. Cozzi, MDPhillip J. Cozzi, MDElmhurst, IL 60126Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-9-199805010-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail You ... Author, Article, and Disclosure InformationAffiliations: Elmhurst, IL 60126Corresponding Author: Phillip J. Cozzi, MD, 447 Cottage Hill, Elmhurst, IL 60126 Previousarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1998Volume 128, Issue 9Page: 778KeywordsChartsChildrenForecastingLibrariesTouch ePublished: 15 August 2000 Issue Published: 1 May 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
INTRACUTANEOUS VACCINES
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection of Aneuploidy in Human Sperm
Authors: R. W. Kapp
Journal: Environmental Health Perspectives (1979)

Adequate methods for monitoring any type of gametic mutation directly in man are virtually nonexistent. A method is presented by which one can monitor Y chromosomal nondisjunction directly in the male gamete by quantifying the number of spermatozoa with two fluorescent bodies (YFF) in 1000 sperm counted. Dried semen slides are stained with quinacrine dihydrochloride and examined under a fluorescent microscope with dark field illumination. This method eliminates the biopsy required for other meiotic studies and further eliminates bias in gametogenic selection by evaluating ejaculated mature spermatozoa. Since chromosomal numerical errors are found in 0.4% of term births and 35% of miscarriages, it is evident that chromosomal aneuploidy constitutes the major mutagenic load in man. In view of the increases observed in the incidence of YFF sperm in patients receiving antineoplastic therapy and in the DBCP-exposed workers, it may be prudent for men who have a history of exposure to mutagens and who are contemplating reproduction to be evaluated by this method prior to attempting conception. Further, this procedure could also be applied to the clinical phase of new drug testing to evaluate the effects of that agent with respect to aneuploidy since the increases in Y chromosomal nondisjunction may well act as a barometer for increases in overall autosomal nondisjunction.
Law and Bioethics
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized, single-centered, phase II clinical trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer.
Authors: Y. Chi, Z. Zheng, A. Zhou, L. Yang, T. Qu, W. Jiang, S. Shi, Y. Sun, Y. Song, S. Kang, J. Wang
Journal: Journal of Clinical Oncology (2011)

e21021 Background: Nimotuzumab, a humanized IgG1 anti-EGFR monoclonal antibody, has demonstrated efficacy associated with an absence of severe skin toxicity in many phase I/II cancer trials. Methods: This is a single-center, randomized, parallel assignment and open-label study of nimotuzumab (N: 200 mg iv on day 1, 8 and 15, repeat every 3 weeks) + cisplatin (C: 30mg/m2/day, on day 1 and day 2, repeat every 3 weeks) + S-1 (S: 80mg/m2/day, twice daily on day 1-14, followed 7 days off), vs cisplatin (C: 30mg/m2/day, on day 1 and day 2, repeat every 3 weeks) + S-1 (S: 80mg/m2/day, twice daily on day 1-14, followed 7 days off) as first line in patients with advanced or metastatic gastric cancer. If tumor control was achieved, NCS and CS were continued until unacceptable toxicity or disease progression. The primary endpoint was ORR and the secondary endpoints included TTP, PFS, 1-year survival rates and safety. Results: 40 patients, 27 men and 13 women, median age 54 years (21-74 years) ECOG PS 0-2 were treated with NCS (n = 20) or CS (n = 20). Up to 2011-01-14, 36 patients (NCS 19 cases compared with CS 17) have undergone efficacy assessment. The objective response rate (ORR) was 63.2% (12/19) in NCS group compared with 64.7% (11/17) in CS group. Until the same day, 18 patients have achieved progression in both groups (NCS 10 vs. FCS 8), median TTP was 5.5 months in NCS group compared with 3 months in CS group, and average TTP was 5.3 months in NCS group compared with 3.1 months in CS group. The incidence of adverse events was similar between both groups. No adverse events of grade 3 skin rash or grade 3 infusion-related reactions were observed. Conclusions: Initial results have demonstrated benefit in TTP improvement and showed a potential improvement of OS. This study supports that nimotuzumab combine with cisplatin and S-1 has better outcomes compare to cisplatin and S-1. The further study is ongoing.
The hepatic microcirculation in the isolated perfused human liver
Authors: J VILLENEUVE
Journal: Hepatology (1996)

In cirrhosis, capillarization of sinusoids could result in impaired exchanges between the hepatocytes and the blood perfusing the liver and contribute to liver failure irrespective of the metabolic capacity of the liver. To characterize anomalies of the hepatic microcirculation, we used the multiple-indicator dilution approach in isolated perfused livers obtained from patients with cirrhosis at the time of transplantation, and from organ donors with normal or near-normal livers or hepatic steatosis. In organ donors, the sinusoidal volume and the permeability of sinusoids to albumin, sucrose, and water were found to be comparable to that of normal dog and rat livers. The sinusoidal volume and the extravascular volume (EVV) accessible to diffusible tracers were larger after hepatic artery than after portal vein injection, probably because of an unshared arterial sinusoidal bed. In cirrhotic livers, two kinds of alterations were found: the appearance of a barrier between the sinusoids and the hepatocytes (capillarization) and intrahepatic shunts. The extravascular space accessible to albumin decreased with increasing severity of cirrhosis, and the diffusion of sucrose in the space of Disse showed a barrier-limited pattern, instead of the normal flow-limited behavior. In cirrhotic livers, a correlation was found between the hepatic extraction of indocyanine green (ICG) and the extravascular space accessible to albumin (r = .84, P < .05), suggesting that the impaired access of this protein-bound dye to the hepatocyte surface contributed to its impaired elimination. Intrahepatic shunts were found between portal and hepatic vein (21% ± 16% of portal flow), but not between hepatic artery and hepatic veins. We conclude that (1) the behavior of diffusible tracers in human livers with normal liver architecture is comparable to that reported in normal animals; (2) the permeability of sinusoids in cirrhotic livers is abnormal, (3) permeability changes are related to changes in liver function in cirrhosis.
Report of solid cancer in patients (pts) with gastrointestinal stromal tumours (GIST)
Authors: M. Chacon, E. Roca, M. Barugel, G. Jankilevich, N. Giacomi, M. Pelati, R. Kowalyszyn, E. Domenechini, M. Galich, E. Huertas
Journal: Journal of Clinical Oncology (2004)

9065 Background: GIST are the most common non-epitelial tumour of the gastrointestinal tract with an increasing incidence after molecular discovery ( KIT gene) and clinical- pathological diagnostic tools (CD117). Data regarding association between GIST and other tumors have so far been limited to some reports of families with multiple GIST, Carney's triad (multiple gastric stromal tumors, pulmonary chondroma, paraganglioma) and GIST in neurofibromatosis pts. The objective is to evaluate the incidence of solid tumors (excluding in situ carcinomas and cutaneus neoplasm non melanoma) in pts with GIST.Patients and Methods: we assessed retrospectively a cohort of pts with histologic (and inmunohistochemistry) diagnosis of GIST from the prospective GATE-D data-base ( period 1999- 2003). Demographic data, characteristics of primary non- GIST tumor and GIST were evaluated. Results: from 86 GIST pts, 9 (10,4%) had prior solid cancer history. Any of the pts developed solid cancer after GIST diagnosis. Characteristics of 86 GIST pts: median age 58 (16–81), male/female 58/28, gastric location 60%, median size 10cm (2–39), advanced disease 36 pts and median follow-up 33 months. Prior to GIST, 9 pts had other cancer history: 2 breast cancer (T2N0M0, T2N1M0), 2 colon cancer (T3N1M0, T2N0M0), 2 cutaneus melanoma (Breslow 1,2 and 1,5 mm, both sentinel nodes negative), 1 prostate (score Gleason 6, PSA 8), 1 renal (T1N0M0) and thyroid (2cm medullar) carcinoma in a 42 years old female. Non GIST tumors occurred 9 (4–15) years (median) before GIST. The median age for the non GIST tumor was 52 (37–70). All tumors were resected and any pt relapsed. All of the non-GIST tumors were considered sporadic (no family history in anyone). Characteristics of the 9 GIST pts who had prior cancer: median age 64 (45–81), gastric location 7/9, median size 6 cm, locally advanced or metastatic 5/9, 4 of them with Imatinib ( all of them in partial response +8,+10,+10,+13 months). Conclusion: in our serie 10,4% of GIST pts had prior cancer history (mainly sporadics). Future studies (clinical and molecular) are going to confirm if GIST are linked to other tumors. No significant financial relationships to disclose.
Brit J Pharmacol &amp; Chemotherapy, London
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Arterial reconstruction to the anterior tibial artery at the ankle
Authors: J. L. Ochsner
Journal: JAMA (1967)

Reconstructive arterial surgical procedures have progressively improved with time. Refinement in instruments, increased surgical experience, and better understanding of the pathophysiology of arterial disease have enabled the surgeon to reestablish circulation to distal sites heretofore believed uncorrectable. Reported here is the technique used to restore blood flow to the distal anterior tibial artery and foot. Progressive refinements in vascular surgical techniques will continue to reduce the limitation in salvage of limbs with arterial disease.
LIGHT May Improve Immune Checkpoint Blockade Response
Journal: Cancer Discovery (2016)

A new study suggests that insufficient T-cell infiltration may explain why a majority of patients do not respond to immunotherapy. Combining PD-L1 inhibitors with antibody-guided LIGHT, a protein that recruits tumor-infiltrating lymphocytes, increased antitumor response in mice, and may have the potential to improve patient response rates to immunotherapy.
Photo/essay. Birth of the red cell
Authors: M. Tavassoli
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diphenylhydantoin Sodium Hepatitis
Authors: Udom Harinasuta
Journal: JAMA (1968)

Drug-induced hepatitis developed five weeks after diphenylhydantoin sodium (Dilantin) administration. The clinical, hematologic, biochemical, and histologic features were consistent with mixed hepatocellular type of hepatic injury due to drug hypersensitivity. Clinical abnormalities and hematologic changes were reproduced by readministration of the drug, but no hepatic abnormalities recurred.
Solvent encephalopathy.
Authors: M D King, R E Day, J S Oliver, M Lush, J M Watson
Journal: BMJ (1981)

Nineteen children aged 8-14 years were admitted over a six-year period with an acute encephalopathy due to toluene intoxication. Seven had a history of euphoria and hallucinations. The remainder presented with coma (4), ataxia (3), convulsions (3), and behaviour disturbance with diplopia (2), A history of glue sniffing was elicited in 14, but in the remainder toluene assay confirmed the diagnosis. Thirteen children recovered completely; five still had psychological impairment and personality change on discharge from hospital but were lost to follow-up, and one has a persistent cerebellar ataxia one year after the acute episode, despite absence of further exposure. Toluene inhalation is an important cause of encephalopathy in children and may lead to permanent neurological damage. Diagnosis is most important if further damage due to continued abuse is to be prevented, and toluene assay is a valuable aid to diagnosis.
Abstracts From the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™
Authors: Lisa Bloudek, Dinara Makenbaeva, Michael Eaddy, Bristol-Myers Squibb, Genevieve Chaput, Desanka Kovacina, Hitesh Bhanabhai, Manuel Borod, Keith Davis, Ravi Goyal, Stephen Able, Jacqueline Brown, ; Li, James Kaye, Christine Chung, Hyunseok Kang, Ana Kiess, Harry Quon, Barbara Murphy, Jill Gilbert, Bryan Loy, William Brooks, Michael Yang, Laura Happe, Thomas Van Gilder, Valentina Petkov, Nadia Howlader, Lynne Penberthy, Kathy Cronin, Robert Lurie
Journal: Journal of the National Comprehensive Cancer Network (2015)

Background: GLEEVEC (imatinib; Novartis Pharmaceuticals Corporation, East Hanover, NJ) was the first tyrosine kinase inhibitor (TKI) approved for use in the United States and remains the most commonly prescribed BCR-
EPIDEMIC CEREBROSPINAL MENINGITIS.
Authors: W. J. CLASS
Journal: JAMA (1899)

<h3>SYMPTOMS.</h3> Among the different classifications of this disease, that of Hisch<sup>49</sup>is probably the best, although like every subject whose different phases approach each other, this disease can not be divided into distinct forms without there being some cases which belong partly in one form and partly in another. Hisch's classification is: 1, meningitis cerebrospinalis epidemica siderans; 2, meningitis cerebrospinalis epidemica abortiva; 3, meningitis cerebrospinalis epidemica intermittans; 4, meningitis cerebrospinalis epidemica typhoides. Under the first form come those cases which commence with violent initial symptoms, agonizing headache, backache, chills, high temperature, uncontrollable vomiting, coma and death within a period varying from twenty-four hours to two or three days. Cases of this nature were of frequent occurrence in the older epidemics, but have of late years become rare. That type called the abortive<sup>50</sup>has also been of unfrequent occurrence in the later epidemics. In it the initial symptoms are
Highlights
Journal: JAMA Internal Medicine (2017)

For this data analysis, Hong and colleagues tried to identify characteristics associated with clinicians more likely to order low-value imaging tests.They performed multivariable logistic regression modeling of imaging rates after acute uncomplicated back pain and headache visits as indicated by commercial insurance claims and demographic data from a large US health insurer.Results showed that ordering low-value imaging on a prior patient, high rates of low-value imaging in another clinical scenario, and ownership of imaging equipment are strong predictors of low-value back and headache imaging. Continuing Medical Education jamanetwork.com/learning A Game-Based Intervention to Increase Activity 1586For this randomized clinical trial, Patel and colleagues tested the effectiveness of a gamification intervention designed using insights from behavioral economics to enhance social incentives within families to increase physical activity.Results showed that gamification designed to leverage insights from behavioral economics to enhance social incentives significantly increased physical activity among families in the community.Kawachi provides the Invited Commentary.
ISOLATED DISEASE OF SCAPHOID BONE OF FOOT
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatocyte-specific deletion of ERK5 worsens insulin resistance in a murine model of non-alcoholic fatty liver disease (NAFLD)
Authors: Giovanni Di Maira, Giulia Lori, Benedetta Piombanti, Maria Letizia Taddei, Paola Chiarugi, Elisabetta Rovida, Cathy Tournier, Fabio Marra
Journal: Journal of Hepatology (2020)
Gastrointestinal Surgery
Authors: Robert E. Hermann
Journal: JAMA (1985)

This new textbook of gastrointestinal surgery provides comprehensive coverage of the surgical problems of the entire gastrointestinal system, including liver, biliary system, and pancreas. The book is attractively published in two volumes, with clear, large, black-and-white illustrations. The text is edited and principally authored by Dr David Fromm and his associates from the Department of Surgery, State University of New York, Syracuse, with several chapters written by eminent invited guest authors from other institutions. This modern textbook on gastrointestinal problems starts off with three chapters on endoscopy, two on diagnostic endoscopy (indications and technique and interpretation of findings) and one on therapeutic endoscopy. A feature throughout is the emphasis on techniques. There is excellent coverage of indications, complications, and results. As in many multiauthored texts, there is some variability in writing and thoroughness of coverage, but the editor has minimized these differences. I found the entire book to be clearly